Quality of life at 3 months · adults experiencing acute traumatic stress symptoms
1 finding from 1 review
Severity of PTSD symptoms ‐ Clinician‐rated · adults experiencing acute traumatic stress symptoms
1 finding from 1 review
Dropouts due to adverse events · adults experiencing acute traumatic stress symptoms
Hydrocortisone showed no clear difference in dropouts due to adverse events at 3 months compared with placebo (low certainty).
1 finding from 1 review
PTSD rate at 3 months · adults experiencing acute traumatic stress symptoms
It is very uncertain whether hydrocortisone changes PTSD rate at 3 months compared with placebo (very low certainty).
1 finding from 1 review
Functional disability at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity of PTSD symptoms · adults (aged 18 and older) exposed to a traumatic event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dropouts due to adverse events · adults (aged 18 and older) exposed to a traumatic event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
PTSD rate at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Functional disability at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment efficacy CAPS, SCID‐IV, PTSS‐10Q‐I · adult participants (18 years and older) who have been exposed to any traumatic events, but who did not meet the diagnostic criteria for…
Hydrocortisone probably leads to lower treatment efficacy CAPS, SCID‐IV, PTSS‐10Q‐I compared with placebo (moderate certainty).
1 finding from 1 review
Hydrocortisone (systemic corticosteroid) vs Placebo or no treatment
Outcome not reported · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
The review found no eligible studies for this question.
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Singh 2010 (hydrocortisone+hyaluronidase 50 vs triamcinolone+hyaluronidase 50): mouth opening reported categorically (trismus) rather than as continuous data, precluding quantitative analysis; authors found no…
1 study · 100 participants
GRADE not reported
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether hydrocortisone plus hyaluronidase (intralesional) changes maximal mouth opening (interincisal distance) compared with placebo or no active treatment (very low certainty).
1 finding from 1 review
Mortality Mortality at latest · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) leads to lower mortality at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower mortality or BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).
1 finding from 1 review
Cerebral palsy · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review
Death or cerebral palsy · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in mortality or cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review
Secondary outcome 3. Number of eczema flares, measured by, for example, ‘escalation of treatment’ or ‘use of topical anti‐inflammatory medications’ Amount of 0.1% hydrocortisone butyrate cream used during the study · adults with eczema
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Moderate